Clinical Trial

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Study acronym: SPARX
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-24
Trial Details
NCT Number NCT07219121
Lead Sponsor Travere Therapeutics, Inc.
Conditions Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
Enrollment 20 participants
Start Date 2025-10-07
Primary Completion 2027-03 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-23